BCRX
BioCryst Pharmaceuticals, Inc.
9.10
+
0.07
0.78%
12 x 9.00
14 x 9.12
bid
ask
13 @ 04:00 PM
9.15+0.05 (0.55%)
Bearish
28
Bullish
78
sentiment
8.68
day range
9.20
7.89
52 week range
19.76
Prev Close9.03
Open9.11
Low8.68
High9.20
Volume3.20M
Avg. Volume4.95M
Market Cap1.69B
Inst. Own71.76%
Beta2.51
Short Ratio4.76
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target17.45
50day MA12.47
200day MA14.12
^DJI
Dow Jones Industrial Average
31261.90
05:03 PM
+
8.80
0.03%
^IXIC
NASDAQ Composite
11354.60
05:15 PM
-
33.90
0.30%
^GSPC
S&P 500
3901.36
05:03 PM
+
0.57
0.01%
AAPL
137.58
-0.01 (0.01%)
Apple Inc.
137.59
11 @ 04:00 PM
13 x 137.56
8 x 137.60
+
0.24
0.17%
GOOG
2187.00
+0.74 (0.03%)
Alphabet Inc.
2186.26
9 @ 04:00 PM
10 x 2186.26
8 x 2186.00
-
28.65
1.29%
AMZN
2159.37
+7.55 (0.35%)
Amazon.com, Inc.
2151.82
10 @ 04:00 PM
8 x 2157.85
12 x 2165.00
+
5.44
0.25%
MSFT
252.94
+0.38 (0.15%)
Microsoft Corporation
252.56
9 @ 04:00 PM
9 x 252.80
8 x 253.00
-
0.58
0.23%
FB
193.81
+0.27 (0.14%)
Meta Platforms, Inc.
193.54
10 @ 04:00 PM
8 x 193.50
11 x 193.55
+
2.25
1.18%
BABA
86.97
+0.18 (0.21%)
Alibaba Group Holding Limited
86.79
10 @ 04:01 PM
12 x 86.82
8 x 86.98
-
0.90
1.03%
NFLX
186.80
+0.45 (0.24%)
Netflix, Inc.
186.35
22 @ 04:00 PM
13 x 186.50
31 x 186.13
+
2.87
1.56%
TSLA
665.40
+1.50 (0.23%)
Tesla, Inc.
663.90
9 @ 04:00 PM
8 x 665.30
10 x 665.40
-
45.52
6.42%
NVDA
166.94
+0.00 (0.00%)
NVIDIA Corporation
166.94
10 @ 04:00 PM
8 x 166.85
11 x 166.97
-
4.30
2.51%
AMD
93.46
-0.04 (0.04%)
Advanced Micro Devices, Inc.
93.50
9 @ 04:00 PM
9 x 93.54
8 x 93.53
-
3.17
3.28%
MU
68.60
-0.30 (0.44%)
Micron Technology, Inc.
68.90
11 @ 04:00 PM
11 x 68.01
10 x 69.00
-
0.50
0.72%
SPY
390.56
+0.93 (0.24%)
SPDR S&P 500 ETF Trust
389.63
12 @ 04:00 PM
14 x 390.38
9 x 390.70
+
0.17
0.04%
TQQQ
27.38
+0.04 (0.15%)
ProShares UltraPro QQQ
27.34
21 @ 04:00 PM
30 x 27.39
12 x 27.40
-
0.24
0.87%
BRK-A
455000.00
-1500.00 (0.33%)
Berkshire Hathaway Inc.
456500.00
9 @ 04:00 PM
9 x 454594.00
8 x 456875.00
+
469.00
0.10%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
This topic has been deleted. Only users with topic management privileges can see it.
-
$BCRX
Who’s it gonna bbbe -
$BCRX Let my people go you raskley rats
-
$BCRX BINGO
-
$BCRX Creatine levels are leveling out …good news
-
‘$BCRX I’m glad to see someone else is concerned about something not just the Sea Turd
-
$BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy
-
$BCRX I think it’s time
-
$BCRX BASTARDS BASTARDS BASTARDS……….
-
$BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.
-
$BCRX You ever felt like you’ve been stabbed in the back…just wondering?
-
-
$BCRX May help control the bleeding…sorry
-
$BCRX @experiment 626 You might have Menorrhagia you might try Neproxen it may help go try the bleeding
-
-
$BCRX Come on they temporarily halted enrollment of new individuals but continue to treat existing patients. Like @Noa said use your noggin for something other than a hat rack
-
So the trial wasn’t halted…
This is an important distinction. Enrollment was halted.
Anybody going to be surprised if they come back a week or two from now and say “yeah, it’s fine, continue enrollment”. And then Pfizer rolls in with an offer, but already has 20M shares somehow?
-
$BCRX 4.28 avg. on 20k but it hurts like hell
-
$BCRX We we’re on edge 13 hrs ago
-
$BCRX What the hell was all of that about?
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
| 2021-02-25 | 2020-12 | -0.25 | -0.34 | -0.09 | -36.00% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
| 2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
| 2022-04-11 | Oppenheimer | Upgrade | Outperform | |
| 2021-12-10 | Oppenheimer | Upgrade | Outperform | |
| 2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-04-17 | ABERCROMBIE GEORGE B | Director | 0.00 | Sale |
| 2022-02-27 | ASELAGE STEPHEN J | Director | 33.16K | Stock Award(Grant) |
| 2022-03-06 | BABU YARLAGADDA S | Officer | 230.06K | Sale |
| 2022-02-27 | HEGGIE THERESA | Director | 16.23K | Stock Award(Grant) |
| 2022-02-27 | INGRAM ROBERT ALEXANDER | Director | 80.06K | Stock Award(Grant) |
| 2022-02-28 | JONES MICHAEL L. | Officer | 11.20K | Sale |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
| 2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
| 2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
| 2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
| 2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-01-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 5.30M | 81.83M | 2.85% |
| 2021-12-30 | Vanguard Total Stock Market Index Fund | 5.11M | 70.78M | 2.75% |
| 2022-01-30 | iShares Russell 2000 ETF | 4.13M | 63.78M | 2.22% |
| 2022-02-27 | Fidelity Select Portfolios - Biotechnology | 2.85M | 47.28M | 1.53% |
| 2021-12-30 | Vanguard Extended Market Index Fund | 2.41M | 33.40M | 1.30% |
| 2021-12-30 | Artisan International Small-Mid Fund | 1.89M | 26.13M | 1.02% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
